Husains
MARKET WRAP
The Sensex was up 267.35 points or 1.1 percent at 23649.22 and the Nifty was up
83.30 points or 1.2 percent at 7191.75. About 1419 shares have advanced, 1118
shares declined, and 147 shares are unchanged.
Dr Reddy Labs, ONGC, Hindalco, Hero MotoCorp, ICICI Bank were top gainers while
Maruti, BHEL, Axis Bank, Reliance and Adani Ports were losers in the Sensex.
P. CLOSE
OPEN
HIGH
LOW
CLOSE
%CHANGE
NIFTY 50
7,108.45
7,177.40
7,215.15
7,127.85
7,191.75
1.17%
NIFTY NEXT 50
17,227.60
17,398.05
17,480.10
17,156.50
17,323.95
0.56%
NIFTY100 LIQ15
2,651.95
2,687.60
2,704.20
2,635.85
2,651.85
0.88%
NIFTY MIDCAP 50
2,781.90
2,812.00
2,837.95
2,752.20
2,797.65
0.57%
www.moneyclassicresearch.com
ASIAN INDEXES
INDEX
OPEN
HIGH
LOW
CLOSE
%CHANGE
NIKKEI 225
16,138.08
16,337.59
16,118.80
16,196.80
2.28%
HANG SENG
19,409.21
19,436.39
19,266.22
19,363.08
2.32%
TAIWAN
8,261.74
8,337.97
8,261.74
8,314.67
1.22%
SSE
2,881.78
2,893.21
2,857.70
2,862.84
-0.16%
P. CLOSE
OPEN
HIGH
LOW
NIFTY BANK
14,119.85
14,301.75
14,385.65
14,180.90
14,298.15
1.26%
5,906.85
5,977.75
5,993.75
5,910.70
5,950.15
0.73%
NIFTY PHARMA
11,148.10
11,315.75
11,446.80
11,252.45
11,371.35
2.00 %
NIFTY IT
10,502.45
10,554.55
10,723.40
10,554.45
10,702.25
1.90%
CURRENT %CHANGE
www.moneyclassicresearch.com
STOCK UPDATE
Monsanto India Falls 4% as Competition Watchdog
Orders Probe
Shares of agri-biotechnology major Monsanto India fell by 4 per cent today after fair
trade regulator CCI ordered a detailed probe against its US-parent joint venture
Mahyco Monsanto Biotech India Limited (MMBL).
Finding prima-facie violation of competition law, CCI has ordered a detailed probe
into alleged abuse of dominance by the Indian arm of the US-based genetically
modified seed giant Monsanto. The stock fell by 3.99 per cent to Rs 1,900.20 -- its 52
-week low -- on BSE. On NSE, it slipped 3.37 per cent to hit one-year low of Rs 1,910.
www.moneyclassicresearch.com
STOCK UPDATE
Cipla advances 2% on acquisition of two US
companies
Shares of Cipla gained 2 percent intraday Thursday on acquisition of two US
companies. The company's UK arm, Cipla (EU) has completed the acquisition of two
US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc.
The acquisition was made by Cipla (EU) through a wholly owned special purpose
vehicle which would merge into InvaGen Pharmaceuticals Inc. after the acquisition.
The combined revenue for the two companies for the year-ended 2015 is over USD
230 million.
Umang Vohra, Global Chief Operating Officer, Cipla said, "The acquisition will further
stre gthe Ciplas prese e i the US phar a euti al arket. I vaGe s ala ed
portfolio, robust manufacturing base and strong R&D capabilities will act as lever to
expand Ciplas rea h i the US arket."
www.moneyclassicresearch.com
RECOMMENDED
ZEEL:-
www.moneyclassicresearch.com
RECOMMENDED
WIPRO:-
www.moneyclassicresearch.com